As more patients are treated concomitantly with SGLT-2 inhibitors such as dapagliflozin and loop diuretics for heart failure with reduced ejection fraction (HFrEF), clinicians should closely monitor for the development of severe dehydration during the initiation period and chronically. Here, SLC5A2 is linked to heart failure.